Halozyme Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow JonesJan 13 23:23 · Ratings

Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $57

Futu NewsJan 13 20:31 · Ratings

Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Cuts Target Price to $57

Futu NewsJan 11 23:31 · Ratings

Piper Sandler Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $53

BenzingaJan 11 01:34 · Ratings

Halozyme Therapeutics (HALO) Is an Incredible Growth Stock: 3 Reasons Why

Zacks Jan 11 00:55

H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $70

Futu NewsJan 10 19:34 · Ratings